PRIMO 2025 | Investigating treatment options for PD-1 refractory melanoma
Merrick Ross, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights the need for effective therapies for PD-1 refractory melanoma, emphasizing that current standard treatment options are limited to single-agent anti-PD-1 therapy in the adjuvant setting. He notes that patients who fail PD-1 in the adjuvant setting may be eligible for clinical trials, but the current consensus is to add anti-CTLA-4 or LAG-3, rather than exploring combination therapies. Dr Ross stresses that identifying an effective therapy for PD-1 refractory patients is the most pressing unmet need, and that neoadjuvant combination studies could potentially address this gap. This interview took place at the PRIMO 2025 congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
